UnknownNot Applicable

Pharmacological Evaluation of Antifungal in Chronic Pulmonary Aspergillosis

France50 participantsStarted 2021-10-01

Plain-language summary

At present, pulmonary diffusion and target antifungal concentrations for APC in patients with sarcoidosis or chronic obstructive pulmonary disease (COPD) are unknown.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient over 18 years of age * Diagnosis of PCA made according to the criteria of Denning et al. Eur Respir J. 2016 * Previously initiated or newly initiated azole antifungal therapy for chronic lung disease complicated by CPA. * Informed patients who did not object to the use of their data. Exclusion Criteria: * Pregnant woman * Co-medication affecting the pharmacokinetics of antifungal agents: Enzyme inducing therapy (rifampin, rifabutin, phenytoin, phenobarbital, efavirenz, nevirapine, etravirine, ritonavir in the case of voriconazole) Drugs that may inhibit the metabolism of antifungal drugs (ritonavir and cobicistat for itraconazole and isavuconazole) * Patients under guardianship/guardianship * Patients without social security coverage

What they're measuring

Ratio of antifungal concentrations in lung samples/plasma samples depending on the type of lung sample (sputum, bronchial aspiration, bronchoalveolar lavage fluid)

Timeframe: At 12 months

Trial details

NCT IDNCT05064605

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-10-01

Contact for this trial

Yurdagül Yuzunhan, MD PhD

+33148956467 yurdagul.yuzunhan@aphp.fr

View on ClinicalTrials.gov More Chronic Respiratory Disease trials